Vertex Pharmaceuticals (VRTX) Operating Expenses (2009 - 2026)

Vertex Pharmaceuticals has reported Operating Expenses for 18 years, with the latest figure at $2.1 billion in Q2 2026.

• On a quarterly basis, Operating Expenses rose 15.07% year-over-year to $2.1 billion in Q2 2026; TTM through Jun 2026 was $7.8 billion, a 4.2% increase from a year earlier, with the FY2025 full-year figure at $7.8 billion, down 30.44% from the prior year.
• Operating Expenses was $2.1 billion for Q2 2026 at Vertex Pharmaceuticals, up from $1.8 billion in the prior quarter.
• The five-year high for Operating Expenses was $6.2 billion in Q2 2024, with the low at $1.1 billion in Q1 2022.
• Average Operating Expenses over 5 years is $1.9 billion, with a median of $1.6 billion recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses jumped 319.98% in 2024, then tumbled 70.56% in 2025.
• Over 5 years, Operating Expenses stood at $1.3 billion in 2022, then gained by 20.49% to $1.5 billion in 2023, then rose by 23.33% to $1.9 billion in 2024, then increased by 5.2% to $2.0 billion in 2025, then advanced by 5.19% to $2.1 billion in 2026.
• The last three Operating Expenses figures came in at $2.1 billion (Q2 2026), $1.8 billion (Q1 2026), and $2.0 billion (Q4 2025), per Business Quant data.